^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

carrimycin

Associations
Trials
Company:
Shenyang Tonglian
Drug class:
Viral replication inhibitor, Protein 50S ribosomal subunit inhibitor
Associations
Trials
8ms
Carrimycin ameliorates lipopolysaccharide and cecal ligation and puncture-induced sepsis in mice. (PubMed, Chin J Nat Med)
Notably, a comparative analysis revealed that CA's anti-inflammatory efficacy surpasses that of equivalent doses of aspirin (ASP) and TIENAM. Collectively, these findings suggest that CA exhibits significant therapeutic potential in sepsis treatment. This discovery provides a foundational theoretical basis for the clinical application of CA in sepsis management.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
aspirin • carrimycin
12ms
Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial. (PubMed, Pharmacol Res)
In tumor patients with sepsis, particularly in those experiencing immunological suppression, carrimycin effectively regulates immune responses by increasing HLA-DR and CD8 T cell levels and plays an anti-infective role, reducing disease severity. (Chictr.org.cn, ID Number: ChiCTR2000032339).
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CRP (C-reactive protein)
|
carrimycin
over1year
Anti-inflammatory effect and antihepatoma mechanism of carrimycin. (PubMed, World J Gastroenterol)
We determined that CAM inhibited inflammation. We also predicted the complex multitargeted effects of CAM that involve multiple pathways and the diversity of these effects in the treatment of liver cancer, which provides a basis and direction for further clinical research.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
|
IL4 elevation
|
carrimycin
over2years
Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by Isovalerylspiramycin I. (PubMed, J Exp Clin Cancer Res)
We demonstrated that ISP I links cancer cell vulnerability to oxidative stress and RNA biogenesis by targeting SELH. This suggests a potential new cancer treatment paradigm, in which the primary therapeutic agent has minimal side-effects and hence may be useful for long-term cancer chemoprevention.
Journal
|
MAPK9 (Mitogen-Activated Protein Kinase 9)
|
carrimycin
almost3years
Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo. (PubMed, Front Pharmacol)
These results show that carrimycin and monomeric isovalerylspiramycin I promoted apoptosis and inhibited proliferation, migration, and invasion of hepatocellular carcinoma cells. Therefore, our discovery suggests anti-tumor capacity for carrimycin and monomeric isovalerylspiramycin I and provides data on potential new drugs for inhibiting hepatocellular carcinoma.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
carrimycin
over3years
Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo. (PubMed, Transl Oncol)
Carrimycin can inhibit the biological activities of OSCC cells in vitro and in vivo, and regulate the PI3K/AKT/mTOR and MAPK pathways.
Preclinical • Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
carrimycin